> but it's also far more likely that the reason we don't use them is that the actual investigation of their effectiveness can't reproduce the results. Or, pass

> but it's also far more likely that the reason we don't use them is that the actual investigation of their effectiveness can't reproduce the results. Or, passing a novel approach through FDA, who are previously not familiar with it, is so prohibitively expensive that nobody wants to invest in it. And since it already has prior art, it's probably also not patentable so you can't even get back the money after you get the approval. Unless such drug can make billions as generic - which is quite rare - there's no point in investing in it, even if it works.